Description

Zixib Tablet (Axitinib Tablets) – Product Description Zixib Tablet contains Axitinib, a targeted anti-cancer medicine used primarily for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It belongs to the tyrosine kinase inhibitor (TKI) class of medicines and works by blocking vascular endothelial growth factor (VEGF) receptors, helping to reduce the blood supply that tumors need to grow and spread. Zixib is prescribed by oncologists for patients with advanced kidney cancer and may be used after prior systemic therapy or according to current treatment guidelines. The tablets are taken orally, with or without food, exactly as directed by the treating physician. Active Ingredient Axitinib Dosage Form Oral Tablets Therapeutic Indications Advanced Renal Cell Carcinoma (RCC) Advanced Kidney Cancer Other approved oncology indications as determined by the treating oncologist How It Works Axitinib selectively inhibits VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3), preventing the formation of new blood vessels that supply nutrients and oxygen to tumors. This helps slow tumor growth and may reduce the spread of cancer. Key Features Targeted therapy for advanced kidney cancer Oral tablet for convenient administration Selective VEGF receptor inhibitor May be used alone or in combination with other oncology treatments Manufactured according to stringent pharmaceutical quality standards Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Note: Zixib Tablet (Axitinib) is a prescription-only medicine and should be used only under the supervision of a qualified oncologist. Regular monitoring of blood pressure, liver function, thyroid function, and other clinical parameters is recommended during treatmenT.